A recent study from one of the five clinical sites for VISICORT, Bristol Eye Hospital, reports that systemic immunosuppression appears to improve long-term graft survival in corneal transplants at high risk of rejection.1
Lead author of the study, Dr Sing-Pey Chow, reports: Immunological graft rejection remains the leading cause of graft failure in corneal transplantation. Systemic immunosuppression with medications such as tacrolimus and mycophenolate mofetil has been successfully used in renal and liver transplantation to improve graft survival. They are also used in corneal transplants at high rejection risk to prevent graft rejection, with the aim of improving graft survival.
This retrospective study reported graft and visual outcomes from 35 full-thickness corneal transplants at high risk of rejection in 29 patients receiving systemic immunosuppression, mainly with tacrolimus or mycophenolate mofetil as monotherapy. With the longest follow-up duration reported to date in high-risk keratoplasty recipients on systemic immunosuppression, 5-year graft survival in this cohort was 73.5%. Rejection episodes occurred in 14 grafts (40%), and episodes were reversible in 10 (71%) grafts. Average time to first rejection episode was 9.9 months, ranging from 1.2 to 15.2 months.
Severe systemic side effects occurred in 3 patients (10%), necessitating cessation of their systemic immunosuppression. This highlights the importance of diligently monitoring patients while they remain on these medications, as well as working closely with physician colleagues to optimise patient outcomes.
Along with co-authors Stuart Cook and Derek Tole, Dr Chow states: Over the next few years, VISICORT will generate a better understanding of adverse immune reactions to tissue transplants as biological samples from over 700 corneal transplant recipients in Europe and the UK is systematically profiled. This will in turn lead to new developments in surveillance, prevention and management of corneal transplantation, particularly for those at high risk of rejection.
This study was presented at World Cornea Congress 2015 in San Diego.
1 Chow S-P, Cook SD, Tole DM. Long-Term Outcomes of High-Risk Keratoplasty in Patients Receiving Systemic Immunosuppression. Cornea 2015, forthcoming.